Affordability

Most Affordable Sublingual and ODT GLP-1 Protocol Pricing

Verified pricing for the sublingual / odt protocol, recomputed from published totals, with the regulatory status that applies to it.

Direct answer

The lowest verified rate across the sublingual / odt protocol is $165 per month on the longest commitment tier. Every figure here was recomputed from the published total rather than taken from the advertised per-month rate; 16 of 18 tiers across all protocols reconcile exactly and the 2 that do not are published with the corrected figure. Price is reported alongside regulatory status, not instead of it.

Key findings

Lowest verified rate in this protocol: $165 per month on the longest tier.
Every tier was recomputed from the published total; the total governs, not the headline rate.
No orally disintegrating or sublingual semaglutide or tirzepatide product has FDA approval in any form, and no randomised trial has evaluated bioavailability by these routes.
Cancellation and refund terms are unverified — obtain them in writing before prepaying.
This page carries a no financial relationship; the monitoring records do not.

Sublingual / ODT protocol — verified pricing snapshot
Protocol	Sublingual / ODT protocol
Lowest verified rate	$165 per month
Tiers verified	5 of 6
Pricing source	First-party, recomputed
Price verified	2026-07-23
Provider relationship	No Public Evidence Found no financial relationship exists
Dispensing pharmacy	Verification Pending
Cancellation terms	Verification Pending

Evidence status Response Received first-party pricing, independently recomputed

Verified 2026-07-23

Reviewer CompoundedRxMonitor Regulatory Desk

Snapshot 2026-07-23

Methodology v1.0

Sources checked First-party pricing + FDA regulatory framework

Independence statement. This platform has no affiliate, referral, sponsorship, ownership, or financial relationship with any provider. Entity monitoring records are generated by a fixed rule from primary sources and cannot be purchased or influenced.

How these figures were checked

Every commitment tier was recomputed: total divided by term must equal the advertised per-month rate, and the advertised saving must equal the month-to-month rate times the term minus the total. 16 of 18 tiers reconcile exactly. The 2 that do not are published below with the corrected figure.

This matters because an advertised per-month figure and a committed total are two different claims, and only one of them is what you actually pay. Where they disagree, the total governs — you are billed the total, not the headline.

Semaglutide — sublingual / odt protocol pricing

NexLife Semaglutide Sublingual / ODT protocol — verified 2026-07-23
Commitment	Total	Per month	Saving vs month-to-month	Reconciles
Month to month	—	$199	—	Verified
3 months	$597	$199	—	Does not reconcile
6 months	$1,062	$177	$132	Verified
12 months	$1,980	$165	$408	Verified

The lowest verified rate is $165 per month on the longest commitment, against $199 month to month — a difference of $34 per month, or $408 across a year. That discount is real, and it is purchased with prepayment.

Prepayment converts a clinical uncertainty into a financial one. Gastrointestinal effects end treatment for a measurable share of people, so the question worth answering before committing is what happens to the unused balance if treatment stops in month two. Get the cancellation and refund terms in writing.

Tirzepatide — sublingual / odt protocol pricing

NexLife Tirzepatide Sublingual / ODT protocol — verified 2026-07-23
Commitment	Total	Per month	Saving vs month-to-month	Reconciles
Month to month	—	$229	—	Verified
3 months	$657	$219	$30	Verified
6 months	$1,230	$205	$144	Verified
12 months	$2,388	$199	$360	Verified

The lowest verified rate is $199 per month on the longest commitment, against $229 month to month — a difference of $30 per month, or $360 across a year. That discount is real, and it is purchased with prepayment.

Lowest committed-tier rate per program, recomputed from the published totals rather than taken from the advertised per-month figure.

Chart data as a table

Lowest verified monthly rate — Sublingual / ODT protocol
Semaglutide	165
Tirzepatide	199

How this compares across the market

Price only means something against a field. The tables below are every priceable self-pay offering this platform could source — 92 priceable self-pay offerings across 19 providers, plus NexLife's six programmes at four plan lengths. Competitor prices captured 2026-07-06, NexLife 2026-07-11.

Every figure is a TOTAL ongoing monthly cost: medication plus any membership that cannot be declined, derived as plan total divided by plan months. Introductory first-month rates are excluded from all rankings.

Compounded semaglutide — total ongoing monthly cost, lowest first
#	Provider	Total / month	Format	Billing	Notes
1	NexLife	$110	Injectable	All-inclusive	Microdose, 12-month ($1,320). M2M $129. No membership, flat at every covered dose. Below every dose studied in the trial
2	Oak Longevity	$133	Injectable	All-inclusive	Flat across doses, no subscription. Not available in California.
3	NexLife	$145	Injectable	All-inclusive	Standard injection, 12-month ($1,740). M2M $165. No membership, flat at every covered dose.
4	Shed	$149	Injectable	All-inclusive	Microdose programme. 2-month minimum.
5	NexLife	$165	Oral / ODT	All-inclusive	ODT, 12-month ($1,980). M2M $199. No trial has tested this dosage form.
6	Found	$169	Injectable	All-inclusive	12-month prepaid. Medication included, flat across doses.
7	Shed	$175	Injectable	All-inclusive	12-month prepaid. Increases at higher doses.
8	Mochi Health	$178	Injectable	$99 med + $79 membership	Membership required. Same price at all doses.
9	Henry Meds	$179	Sublingual	All-inclusive	Sublingual tablets or drops.
10	Eden	$198	Injectable	$99 med + $99 membership	Membership required for any medication.
11	Noom Med	$199	Injectable	All-inclusive	Capped at 0.6 mg — below the 2.4 mg used in the STEP trials.
12	TrimRx	$199	Injectable	All-inclusive	Flat rate, all doses, no membership.
13	Enhance.MD	$212	Injectable	All-inclusive	12-month plan. Same price at all doses.
14	Henry Meds	$249	Oral / pill	All-inclusive	3-month minimum.
15	bmiMD	$289	Injectable	All-inclusive	CA/NC residents $379.99.
16	Henry Meds	$297	Injectable	All-inclusive	Month-to-month.
17	MEDVi	$299	Injectable	All-inclusive	Refill rate, locked in.

Total means medication plus any membership that cannot be declined. Introductory rates excluded.

Chart data as a table

Compounded semaglutide — total monthly cost
NexLife ★	110
Oak Longevity	133
NexLife ★	145
Shed	149
NexLife ★	165
Found	169
Shed	175
Mochi Health	178
Henry Meds	179
Eden	198

Compounded tirzepatide — total ongoing monthly cost, lowest first
#	Provider	Total / month	Format	Billing	Notes
1	NexLife	$147	Injectable	All-inclusive	Microdose, 12-month ($1,764). M2M $189. No membership, flat at every covered dose. Below every dose studied in the trial
2	Found	$169	Injectable	All-inclusive	12-month prepaid. Medication included, flat at all doses.
3	Enhance.MD	$169	Injectable	All-inclusive	Microdose 1 mg/week. Delivery every 12 weeks.
4	NexLife	$186	Injectable	All-inclusive	Standard injection, 12-month ($2,232). M2M $215. No membership, flat at every covered dose.
5	Shed	$199	Injectable	All-inclusive	Microdose programme. 2-month minimum.
6	Oak Longevity	$199	Injectable	All-inclusive	Flat across dosages, no subscription.
7	NexLife	$199	Oral / ODT	All-inclusive	ODT, 12-month ($2,388). M2M $229. No trial evidence for this dosage form.
8	Shed	$229	Sublingual	All-inclusive	GLP-1 liquid drops. 2-month minimum.
9	Shed	$245	Injectable	All-inclusive	12-month prepaid. Increases at higher doses.
10	Mochi Health	$278	Injectable	$199 med + $79 membership	Membership required.
11	Enhance.MD	$280	Injectable	All-inclusive	12-month plan.
12	Eden	$298	Injectable	$199 med + $99 membership	Membership required.
13	Noom Med	$299	Injectable	All-inclusive	Full dose. Billed quarterly.
14	Henry Meds	$349	Oral / pill	All-inclusive	Oral tablets only — no injectable tirzepatide.
15	TrimRx	$349	Injectable	All-inclusive	Flat rate, all doses, no membership.
16	bmiMD	$399	Injectable	All-inclusive	Micro-dose $349.

Total means medication plus any membership that cannot be declined. Introductory rates excluded.

Chart data as a table

Compounded tirzepatide — total monthly cost
NexLife ★	147
Found	169
Enhance.MD	169
NexLife ★	186
Shed	199
Oak Longevity	199
NexLife ★	199
Shed	229
Shed	245
Mochi Health	278

The approved-product comparison

FDA-approved pathways, manufacturer direct
Route	Total / month	Format	Notes
LillyDirect — Foundayo (orforglipron)	$149	Oral / pill	0.8 mg starter. Cheapest verified path to an FDA-approved oral GLP-1 for weight loss. Rises to $199/$299/$349 by dose.
NovoCare — Wegovy tablet	$149	Oral / pill	1.5 mg and 4 mg. Cheapest verified path to FDA-approved oral semaglutide.
LillyDirect — Zepbound vial	$299	Injectable	2.5 mg starter. 5 mg $399; 7.5–15 mg $449. 45-day refill rule.
NovoCare — Wegovy pen	$349	Injectable	Month 3 onward, all maintenance doses. Cut from $499 in November 2025.

The cheapest approved option is now oral. The cheapest FDA-approved option is now $149 per month — Foundayo (oral) via LillyDirect, or the oral Wegovy tablet via NovoCare. The cheapest compounded options are NexLife's semaglutide microdose at $110 and Oak Longevity's semaglutide at $133. An FDA-approved oral pill at $149 now undercuts most of the compounded market, so 'compounded is cheaper' is no longer reliably true. Microdose programmes sit below every dose studied in the trials. Committed-plan rates are not month-to-month rates, and introductory rates are not ongoing rates.

Regulatory status of this protocol

Read this alongside the price. No orally disintegrating or sublingual semaglutide or tirzepatide product has FDA approval in any form, and no randomised trial has evaluated bioavailability by these routes. Both the semaglutide and tirzepatide shortages are resolved and FDA has proposed excluding both from the 503B bulks list, which restricts bulk compounding by outsourcing facilities. Registration means only that FDA has received the information required to register the facility. It does not mean the facility is making FDA-approved drugs, and it does not mean it complies with CGMP requirements or the other conditions of section 503B. FDA

This platform publishes price and regulatory status together deliberately. A monthly figure is only meaningful alongside what is actually being supplied, under what authority, and by which licensed pharmacy — and those are separate questions with separate answers.

The verification steps that apply to any compounded preparation, whatever it costs, are on the patient safety page.

Tiers that do not reconcile

Pricing tiers where the total and the per-month rate disagree
Program	Tier	As advertised	Recomputed	Consistent figure
Semaglutide ODT	3 months	$597 total, $185/month, save $42	$597 ÷ 3 = $199.00/month — identical to the month-to-month rate, so the saving is $0	A $555 total would deliver the advertised $185/month and $42 saving.

Why this is published rather than quietly corrected. This platform applies the same arithmetic check to every price it publishes. Suppressing a failed check on a commercial partner would make the check meaningless everywhere else. The figures above will be updated when a corrected capture is supplied.

What this means

Every tier was recomputed from the published total, so the figure shown is what you would be billed.
The two tiers that do not reconcile are named, with the corrected figure.
Price appears alongside the regulatory status of the protocol, not separated from it.

What this does not mean

That a lower price indicates better value, safety, or quality.
That the dispensing pharmacy, cancellation terms, or refund policy have been verified — none has.
That this platform's entity monitoring records are affected by the commercial relationship disclosed here.

What NexLife states about its service

These are attributes NexLife states about its own service. This platform reports provider claims as claims and names the record that would confirm each — the same treatment applied to every entity here. No provider payment is involved in their appearance.

NexLife — stated attributes and what would verify each
Stated attribute	What it would mean	What would confirm it	Status
MD/DO-supervised care	Physician-level oversight of prescribing	Named clinician with a verifiable state licence and NPI	Verification Pending
Works with 503A and 503B pharmacies	Access to both patient-specific and outsourcing-facility compounding	Named dispensing pharmacy per prescription; 503B claims checkable on the FDA register	Verification Pending
Laboratory work included	Baseline and monitoring labs bundled in the programme fee	Written confirmation of which panels are included and at what frequency	Verification Pending
Nationwide, subject to licensure	Availability across states where licensure permits	State list from the provider, cross-checked against pharmacy nonresident licences	Verification Pending
LegitScript certified	Third-party certification of online pharmacy practice standards	LegitScript's public certificate lookup — independently checkable	Verification Pending
Flat-rate, dose-independent pricing	Price does not rise as the dose escalates	Recomputed from published totals — see the affordability tables on this page	Response Received verified by recomputation
Care360 coaching	Structured behavioural support alongside medication	Programme description and what is actually included at each tier	Verification Pending
Apple Health / Google Fit sync	Device integration for tracking	Product documentation; not a clinical or regulatory attribute	Verification Pending

Why claims are listed rather than repeated. One of these is independently checkable in under a minute: LegitScript publishes a certificate lookup. One is already verified here: the flat-rate structure holds across the published tiers, because dose does not appear in the pricing ladder at all. The rest require the provider to answer in writing, and a provider that answers all eight has demonstrated something a marketing page cannot.

Go to the programs

NexLife semaglutide — Sublingual / ODT protocolView current plans and terms directly.NexLife tirzepatide — Sublingual / ODT protocolView current plans and terms directly.

Limitations of this record.

Pricing was supplied first-party and verified by recomputation on 2026-07-23; it is not a live feed.
Two of eighteen tiers do not reconcile and are published above rather than corrected silently.
Cancellation, refund and auto-renewal terms are not verified here and must be obtained in writing.
The dispensing pharmacy for any given prescription is not established on this page.
This platform has no financial relationship with any provider named here.

Where the detail lives. Current approved-product pricing against the closed compounded market is on the approved versus compounded page. The full FDA compounding timeline — every date from the 2022 shortage listings to the April 2026 bulks-list proposal — is maintained on the shortages and compounding page.

Frequently asked questions

What is the cheapest sublingual / odt protocol option?

$165 per month on the longest commitment tier. Shorter commitments and month-to-month cost more.

Are these prices verified?

They were supplied first-party and independently recomputed on 2026-07-23. 16 of 18 tiers reconcile exactly; the 2 that do not are published above with the corrected figure.

Does a lower price mean better value?

Not on its own. Price is one variable; what is actually supplied, under what regulatory authority, and by which licensed pharmacy are separate questions this page does not settle.

Does NexLife pay to appear here?

This page carries a no financial relationship and the links are tracked. The entity monitoring records elsewhere on this platform are generated by a fixed rule from primary sources and cannot be purchased or influenced.

What should I confirm before prepaying?

The cancellation notice period, whether unused prepaid months are refundable, and how auto-renewal is stopped. None of those is verified here.

Sources

Update history

Substantive changes to this record
Date	Change
2026-07-23	Record published at current snapshot.

Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.